Skip to main content
. 2015 Oct 19;6(42):44179–44190. doi: 10.18632/oncotarget.6175

Figure 1. Proposed scheme for the clinical application of CAR-T cell-derived exosomes.

Figure 1

Peripheral blood sample (30-50 ml) is taken from cancer patient. Total nucleated cells are isolated through density separation or red blood cell lysate solution and cultured with T cell stimulators, such as antibodies for CD3 and CD28. CD8+ T cells are selected through positive or negative selection method and transfected with CARs through viral or non-viral transfection technology. CAR-engineered T cells are ex vivo expanded in the presence of IL-2. CAR-T cell-derived exosomes are isolated from culture media as described in the text. Exosomes are characterized by biomarker assessment and quantified by protein assay. Exosomes are infused into the same patient after preconditioning with chemotherapy.